| |  Online-Ressource |
|---|
| Verfasst von: | Veinalde, Rūta [VerfasserIn]  |
|---|
| | Pidelaserra Martí, Gemma [VerfasserIn] |
|---|
| | Moulin, Coline [VerfasserIn] |
|---|
| | Tan, Chin Leng [VerfasserIn] |
|---|
| | Schäfer, Theresa E. [VerfasserIn] |
|---|
| | Kang, Na [VerfasserIn] |
|---|
| | Ball, Claudia R. [VerfasserIn] |
|---|
| | Leichsenring, Jonas [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| | Kaderali, Lars [VerfasserIn] |
|---|
| | Jäger, Dirk [VerfasserIn] |
|---|
| | Ungerechts, Guy [VerfasserIn] |
|---|
| | Engeland, Christine Elisabeth [VerfasserIn] |
|---|
| Titel: | Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model |
|---|
| Verf.angabe: | Rūta Veinalde, Gemma Pidelaserra-Martí, Coline Moulin, Chin Leng Tan, Theresa E. Schäfer, Na Kang, Claudia R. Ball, Jonas Leichsenring, Albrecht Stenzinger, Lars Kaderali, Dirk Jäger, Guy Ungerechts, Christine E. Engeland |
|---|
| Jahr: | 2022 |
|---|
| Umfang: | 16 S. |
|---|
| Fussnoten: | Elektronische Reproduktion der Druck-Ausgabe 16. Januar 2023 ; Gesehen am 31.01.2023 |
|---|
| Titel Quelle: | Enthalten in: Frontiers in immunology |
|---|
| Ort Quelle: | Lausanne : Frontiers Media, 2010 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 13(2022), Artikel-ID 1096162, Seite 1-16 |
|---|
| ISSN Quelle: | 1664-3224 |
|---|
| Abstract: | IntroductionPancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB. In this work, we investigated the combination of anti-PD-1 and oncolytic measles vaccine in an immunocompetent transplantable PDAC mouse model.MethodsWe characterized tumor-infiltrating T cells by immunohistochemistry, flow cytometry and T cell receptor sequencing. Further, we performed gene expression profiling of tumor samples at baseline, after treatment, and when tumors progressed. Moreover, we analyzed systemic anti-tumor and anti-viral immunity.ResultsCombination treatment significantly prolonged survival compared to monotherapies. Tumor-infiltrating immune cells were increased after virotherapy. Gene expression profiling revealed a unique, but transient signature of immune activation after combination treatment. However, systemic anti-tumor immunity was induced by virotherapy and remained detectable even when tumors progressed. Anti-PD-1 treatment did not impact anti-viral immunity.DiscussionOur results indicate that combined virotherapy and ICB induces anti-tumor immunity and reshapes the tumor immune environment. However, further refinement of this approach may be required to develop its full potential and achieve durable efficacy. |
|---|
| DOI: | doi:10.3389/fimmu.2022.1096162 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.3389/fimmu.2022.1096162 |
|---|
| | kostenfrei: Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1096162 |
|---|
| | DOI: https://doi.org/10.3389/fimmu.2022.1096162 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1832748146 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model / Veinalde, Rūta [VerfasserIn]; 2022 (Online-Ressource)
